Hjem › Ikke-småcellet lungekreft › North Dakota › Fargo
Kliniske studier for Ikke-småcellet lungekreft i Fargo, ND
15 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Fargo (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruttererFase 3
- Essentia Health Cancer Center-South University Clinic, Fargo
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekruttererFase 2
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RekruttererFase 3
- Sanford Fargo Medical Center ( Site 3236), Fargo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057), Fargo
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
RekruttererObservasjonsstudie
- Sanford Fargo Medical Center ( Site 0039), Fargo
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
RekruttererFase 1/2
- Sanford Fargo Medical Center ( Site 0039), Fargo
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
RekruttererFase 2
- Sanford Fargo Medical Center ( Site 0039), Fargo
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 2
- Sanford Roger Maris Cancer Center, Fargo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Essentia Health Cancer Center-South University Clinic, Fargo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Fargo
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Fargo
- Lungekreft13 studier
- Kreft (alle typer)10 studier
- Melanom9 studier
- Fedme9 studier
- Overvekt8 studier
- Prostatakreft8 studier
- Brystkreft7 studier
- Kolorektal kreft7 studier
- Type 2-diabetes6 studier
- Pankreaskreft6 studier
- Plateepitelcancer i hode og hals6 studier
- Endetarmskreft6 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.